专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07070797B2 Method of treating hematologic tumors and cancers 失效
公开(公告)号：US07070797B2
公开(公告)日：2006-07-04
申请号：US10209388
申请日：2002-07-31
申请人： Arthur B. Pardee , Kenneth Anderson , Deepak Gupta , Chiang Li , Youzhi Li
发明人： Arthur B. Pardee , Kenneth Anderson , Deepak Gupta , Chiang Li , Youzhi Li
IPC分类号： A61F13/00
CPC分类号： A61K45/06 , A61K31/136 , A61K31/337 , A61K31/352 , A61K31/353 , A61K31/4184 , A61K31/4745 , A61K31/475 , A61K31/704 , A61K31/7048 , A61K2300/00
摘要： Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably β-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

2. 发明申请

US20060183793A1 Method of treating hematologic tumors and cancers 审中-公开
公开(公告)号：US20060183793A1
公开(公告)日：2006-08-17
申请号：US11315430
申请日：2005-12-21
申请人： Arthur Pardee , Kenneth Anderson , Deepak Gupta , Chiang Li , Youzhi Li
发明人： Arthur Pardee , Kenneth Anderson , Deepak Gupta , Chiang Li , Youzhi Li
IPC分类号： A61K31/353
CPC分类号： A61K45/06 , A61K31/136 , A61K31/337 , A61K31/352 , A61K31/353 , A61K31/4184 , A61K31/4745 , A61K31/475 , A61K31/704 , A61K31/7048 , A61K2300/00
摘要： Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably β-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

3. 发明授权

US06875745B2 Method and composition for the treatment of cancer 失效
标题翻译：治疗癌症的方法和组成
公开(公告)号：US06875745B2
公开(公告)日：2005-04-05
申请号：US10683199
申请日：2003-10-09
申请人： Arthur B. Pardee , Chiang J. Li , Youzhi Li
发明人： Arthur B. Pardee , Chiang J. Li , Youzhi Li
IPC分类号： C07D311/92 , A61K31/122 , A61K31/337 , A61K31/35 , A61K31/352 , A61K31/4184 , A61K31/427 , A61K31/437 , A61K31/704 , A61K31/7042 , A61K38/00 , A61K45/00 , A61K45/06 , A61P35/00 , A61K31/70 , A61K31/519 , A61K31/505
CPC分类号： A61K31/337 , A61K31/122 , A61K31/35 , A61K45/06 , Y10S514/922 , A61K31/335 , A61K2300/00
摘要： We have discovered that the administration of a G1 and/or S phase drug such as β-lapachone in combination with a G2/M drug such as a taxane derivative such as paclitaxel resulted in a greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a β-lapachone, or a derivative or analog thereof.
摘要翻译：我们已经发现，G1和/或S期药物如β-萘普生与G2 / M药物如紫杉烷衍生物如紫杉醇的组合的给药导致了大于添加剂（即协同）的减少与单独施用这些试剂相比，肿瘤数目（和肿瘤体积）。此外，没有观察到毒性或体重减轻的迹象。本发明涉及使用组合例如紫杉烷衍生物，优选紫杉醇和β-拉帕酮或其衍生物或类似物来治疗哺乳动物肿瘤的方法。

4. 发明授权

US06664288B1 Method and composition for the treatment of cancer 失效
标题翻译：治疗癌症的方法和组成
公开(公告)号：US06664288B1
公开(公告)日：2003-12-16
申请号：US09958479
申请日：2002-02-07
申请人： Arthur B. Pardee , Chiang J. Li , Youzhi Li
发明人： Arthur B. Pardee , Chiang J. Li , Youzhi Li
IPC分类号： A61K3135
CPC分类号： A61K31/337 , A61K31/122 , A61K31/35 , A61K45/06 , Y10S514/922 , A61K31/335 , A61K2300/00
摘要： We have surprisingly discovered that the administration of a G1 and/or S phase drug such as &bgr;-lapachone in combination with a G2/M drug such as a taxame derivative such as paclitaxel resulted in an unexpected greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a &bgr;-lapachone, or a derivative or analog thereof.
摘要翻译：我们惊奇地发现，G1和/或S期药物如β-拉帕酮与G2 / M药物如紫杉醇衍生物如紫杉醇的组合的给药导致意想不到的大于添加剂（即协同）的减少与单独施用这些药物相比，肿瘤数目（和肿瘤体积）。此外，没有观察到毒性或体重减轻的迹象。本发明涉及使用组合例如紫杉烷衍生物，优选紫杉醇和β-拉帕酮或其衍生物或类似物来治疗哺乳动物肿瘤的方法。

5. 发明申请

US20080146584A1 Method of treating cancers using beta-lapachone or analogs or derivatives thereof 审中-公开
标题翻译：使用β-萘酮或其类似物或其衍生物治疗癌症的方法
公开(公告)号：US20080146584A1
公开(公告)日：2008-06-19
申请号：US12070601
申请日：2008-02-20
申请人： Chiang Li , Youzhi Li
发明人： Chiang Li , Youzhi Li
IPC分类号： A61K31/506 , A61K31/352 , A61P35/00
CPC分类号： A61K45/06 , A61K31/35 , A61K31/506 , A61K2300/00
摘要： Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint activator, which is preferably β-lapachone, or a derivative or analog thereof, combined with an oncogenic kinase modulator, preferably imatinib. This combination of the cell cycle checkpoint activator with the oncogenic kinase modulator results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint activator and the oncogenic kinase modulator, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.
摘要翻译：癌症和/或恶性肿瘤可以通过施用细胞周期检查点激活剂来治疗，细胞周期检查点激活剂优选地是β-拉帕酮，或其衍生物或类似物，与致癌激酶调节剂，优选伊马替尼组合。细胞周期检查点激活剂与致癌激酶调节剂的这种组合导致意想不到的大于癌细胞中的添加（即协同）凋亡。本发明包括通过施用细胞周期检查点激活剂和致癌激酶调节剂的组合来治疗癌症的方法，包括在这些方法中使用的药物的组合的药物组合物以及药物试剂盒。

6. 发明申请

US20060142271A1 Novel lapacho compounds and methods of use thereof 审中-公开
标题翻译：新型茄科化合物及其使用方法
公开(公告)号：US20060142271A1
公开(公告)日：2006-06-29
申请号：US10528295
申请日：2003-09-17
申请人： Klaus Muller , Andreas Sellmer , June Salvesen , Chiang Li , Youzhi Li , Xianggao Sun
发明人： Klaus Muller , Andreas Sellmer , June Salvesen , Chiang Li , Youzhi Li , Xianggao Sun
IPC分类号： A61K31/55
CPC分类号： C07D307/92 , C07D333/74
摘要： The invention provides new synthetic lapacho derivatives as well as methods of use thereof. These compounds can be used in pharmaceutical compositions for the treatment or prevention of cell proliferation disorders. These compounds can also be used in the treatment or prevention of psoriasis or cancer or precancerous conditions.
摘要翻译：本发明提供了新的合成拉舌乐衍生物及其使用方法。这些化合物可以用于治疗或预防细胞增殖障碍的药物组合物中。这些化合物也可用于治疗或预防牛皮癣或癌症或癌前病症。

7. 发明授权

US07361691B2 Method of treating cancers using β-lapachone or analogs or derivatives thereof 失效
公开(公告)号：US07361691B2
公开(公告)日：2008-04-22
申请号：US10726467
申请日：2003-12-02
申请人： Chiang Li , Youzhi Li
发明人： Chiang Li , Youzhi Li
IPC分类号： A61K31/506 , A61K31/497
CPC分类号： A61K45/06 , A61K31/35 , A61K31/506 , A61K2300/00
摘要： Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint activator, which is preferably β-lapachone, or a derivative or analog thereof, combined with an oncogenic kinase modulator, preferably imatinib. This combination of the cell cycle checkpoint activator with the oncogenic kinase modulator results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint activator and the oncogenic kinase modulator, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

8. 发明申请

US20050171031A1 Method and composition for the treatment of cancer 审中-公开
标题翻译：治疗癌症的方法和组成
公开(公告)号：US20050171031A1
公开(公告)日：2005-08-04
申请号：US11069637
申请日：2005-03-01
申请人： Arthur Pardee , Chiang Li , Youzhi Li
发明人： Arthur Pardee , Chiang Li , Youzhi Li
IPC分类号： C07D311/92 , A61K31/122 , A61K31/337 , A61K31/35 , A61K31/352 , A61K31/4184 , A61K31/427 , A61K31/437 , A61K31/704 , A61K31/7042 , A61K38/00 , A61K45/00 , A61K45/06 , A61P35/00 , A61K31/7048 , A61K31/4745 , A61K31/404 , A61K31/12
CPC分类号： A61K31/337 , A61K31/122 , A61K31/35 , A61K45/06 , Y10S514/922 , A61K31/335 , A61K2300/00
摘要： We have discovered that the administration of a G1 and/or S phase drug such as β-lapachone in combination with a G2/M drug such as a taxane derivative such as paclitaxel resulted in a unexpected greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a β-lapachone, or a derivative or analog thereof.
摘要翻译：我们已经发现，G1和/或S期药物如β-拉帕酮与G2 / M药物如紫杉烷衍生物如紫杉醇的组合的给药导致意想不到的大于添加剂（即协同）的减少与单独施用这些药物相比，肿瘤的数量（和肿瘤体积）。此外，没有观察到毒性或体重减轻的迹象。本发明涉及使用组合例如紫杉烷衍生物，优选紫杉醇和β-拉帕酮或其衍生物或类似物来治疗哺乳动物肿瘤的方法。

9. 发明申请

US20050119352A1 Method of treating cancers 失效
标题翻译：治疗癌症的方法
公开(公告)号：US20050119352A1
公开(公告)日：2005-06-02
申请号：US10726467
申请日：2003-12-02
申请人： Chiang Li , Youzhi Li
发明人： Chiang Li , Youzhi Li
IPC分类号： A61K31/12 , A61K31/35 , A61K45/06
CPC分类号： A61K45/06 , A61K31/35 , A61K31/506 , A61K2300/00
摘要： Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint activator, which is preferably β-lapachone, or a derivative or analog thereof, combined with an oncogenic kinase modulator, preferably imatinib. This combination of the cell cycle checkpoint activator with the oncogenic kinase modulator results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint activator and the oncogenic kinase modulator, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.
摘要翻译：癌症和/或恶性肿瘤可以通过施用细胞周期检查点激活剂来治疗，细胞周期检查点激活剂优选地是β-拉帕酮，或其衍生物或类似物，与致癌激酶调节剂，优选伊马替尼组合。细胞周期检查点激活剂与致癌激酶调节剂的这种组合导致意想不到的大于癌细胞中的添加（即协同）凋亡。本发明包括通过施用细胞周期检查点激活剂和致癌激酶调节剂的组合来治疗癌症的方法，包括在这些方法中使用的药物的组合的药物组合物以及药物试剂盒。

10. 发明授权

US09745278B2 Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors 有权
公开(公告)号：US09745278B2
公开(公告)日：2017-08-29
申请号：US12677513
申请日：2008-09-10
申请人： Chiang Jia Li , Harry Rogoff , Youzhi Li , Jifeng Liu , Wei Li
发明人： Chiang Jia Li , Harry Rogoff , Youzhi Li , Jifeng Liu , Wei Li
IPC分类号： A61K31/655 , C07D307/92 , A61K31/38 , C07D333/74
CPC分类号： C07D307/92 , A61K31/38 , C07D333/74 , Y02A50/465
摘要： The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical composition of relevant compounds, and to the specific methods of administration of these compounds.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式